Emma joined Bristol Myers Squibb in 2018 and is responsible for leading Oncology Discovery in Cambridge. At our Kendall Square, Cambridge research facility, the Mechanisms of Cancer Resistance Thematic Research Center is primarily focused on understanding resistance to standard of care cancer therapies, studying patients who do not respond or build a resistance to immune checkpoints drugs such as Nivolumab and Ipilumimab, and targeted therapies such as PARPi, with the goal to discover medicines for these patient populations with unmet medical needs. As head of R&ED for the site, Emma partners with the Cambridge Leadership Team to develop a cohesive site vision, objectives, and culture that is aligned with and enables our global strategy. Emma brings a wealth of experience from both East Coast and West Coast; she started her industry career at DNAX Research Institute/Schering-Plough in Palo Alto, CA where she was responsible for building and leading the Oncology Research Group. Emma joined Novartis Institutes for Biomedical Research (NIBR) as Site Head and Vice President of Oncology in Emeryville, CA and later became Vice President of Oncology Biotherapeutics in Cambridge, MA where she was responsible for the design, development, strategy and implementation of the biologics oncology portfolio. Emma transitioned to Jounce Therapeutics a small immuno-oncology company based in Cambridge, MA where as the Head of Research, she had oversight of all discovery and translational research to support clinical programs and was involved in all business aspects of the company. Emma holds a Ph.D. from Imperial Cancer Research Fund, London England and performed post-doctoral work for Cold Spring Harbor labs and Harvard Medical School, Massachusetts General Hospital Cancer Center.